Skip to main content

Table 3 Follow-up on patients at 2 years clinical outcomes

From: Biodegradable polymer drug-eluting stents versus second-generation drug-eluting stents in patients with and without diabetes mellitus: a single-center study

Clinical outcomes (n, %) DM No-DM
G2‑DES
N = 1862 		BP‑DES
N = 421 		p G2‑DES
N = 4232 		BP‑DES
N = 1151 		P
MACE 219 (11.8) 60 (14.3) 0.159 403 (9.5) 129 (11.2) 0.089
 All-cause death 27 (1.5) 6 (1.4) 0.969 40 (0.9) 16 (1.4) 0.187
 Cardiac death 16 (0.9) 2 (0.5) 0.554 25 (0.6) 6 (0.5) 0.782
 Non-fatal MI 37 (2.0) 15 (3.6) 0.050 75 (1.8) 17 (1.5) 0.493
 ST 20 (1.1) 5 (1.2) 0.797 32 (0.8) 6 (0.5) 0.399
Revascularization 145 (7.8) 39 (9.3) 0.315 279 (6.6) 89 (7.7) 0.174
 TVR 81 (4.4) 24 (5.7) 0.232 136 (3.2) 59 (5.1) 0.002
 TLR 66 (3.5) 22 (5.2) 0.106 92 (2.2) 52 (4.5) < 0.001
 Stroke 26 (1.4) 4 (1.0) 0.468 51 (1.2) 15 (1.3) 0.789
Bleeding 124 (6.7) 21 (5.0) 0.204 310 (7.3) 79 (6.9) 0.592
 BARC 2_5 50 (2.7) 8 (1.9) 0.355 123 (2.9) 31 (2.7) 0.701
 BARC 3_5 8 (0.4) 1 (0.2) > 0.999 24 (0.6) 4 (0.3) 0.358
  1. DM diabetes mellitus, G2-DES second generation drug-eluting stent, BP-DES biodegradable polymer drug-eluting stent, MACE major adverse cardiac events, MI myocardial infarction, ST stent thrombosis, TVR target vessel revascularization, TLR target lesion revascularization, BARC Bleeding Academic Research Consortium definition
Back to article page